
    
      RATIONALE:

      Topical resiniferatoxin (RTX) administrated to the bladder may be effective in decreasing the
      symptoms associated with interstitial cystitis through its action on pain sensing neurons.

      PURPOSE:

      Randomized, double-blind, placebo-controlled, Phase 2 trial to determine the safety and
      efficacy of RTX in patients with interstitial cystitis.
    
  